



LKT Laboratories, Inc.

Acalabrutinib

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID A081014

CAS No. 1420477-60-6

Chemical Name

Synonym ACP-196

Formula $C_{26}H_{23}N_7O_2$

Formula Wt. 465.52

Melting Point


Purity $\geq 99\%$

Solubility

Store Temp $-20^{\circ}C$

Ship Temp Ambient

Description Acalabrutinib is an inhibitor of Bruton's tyrosine kinase (BTK). It showed increased selectivity compared with first generation BTK inhibitors such as ibrutinib while offering similar antitumor efficacy in mouse models of chronic lymphocytic leukemia. It has been approved for the treatment of patients with relapsed mantle cell lymphoma (MCL), a unique type of non-Hodgkin lymphoma characterized by the overexpression of cyclin D1. It is currently being investigated as a front line treatment for MCL. TEST!!!!!!



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
A081014	5 mg	\$85.00
A081014	25 mg	\$225.00
A081014	100 mg	\$650.00

References Herman S., Montraveta A., et al. The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. Clin Cancer Res. 23(11):2831-41 (2016). PMID:27903679.

Witzig T., Inwards D. Acalabrutinib for mantle cell lymphoma. Blood. 133(24):2570-74 (2019). PMID: 30967367.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.